{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T10:36:14Z","timestamp":1767695774437,"version":"3.48.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.prro.2025.07.008","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T15:15:06Z","timestamp":1756134906000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer With Radiosurgery"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-3226","authenticated-orcid":false,"given":"James B.","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin W.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Summer S.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Jairam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy M.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Pendyala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald D.","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Sapir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.07.008_bib0001","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0002","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0003","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0004","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: An ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2019.02.006","article-title":"Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study","volume":"130","author":"Arrieta","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prro.2025.07.008_bib0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12931-019-1235-3","article-title":"Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients","volume":"20","author":"Aoki","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.prro.2025.07.008_bib0007","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non\u2013small cell lung cancer: A phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0008","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.21037\/tlcr-20-1123","article-title":"Clinical prognostic factors in surgically treated oligometastatic non-small cell lung cancer: A systematic review","volume":"10","author":"Bertolaccini","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.prro.2025.07.008_bib0009","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2020.12.029","article-title":"Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study","volume":"152","author":"Blake-Cerda","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prro.2025.07.008_bib0011","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ijc.33546","article-title":"Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis","volume":"149","author":"Buergy","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.prro.2025.07.008_bib0012","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mdu370","article-title":"Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients","volume":"25","author":"Collen","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0013","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jtho.2018.07.098","article-title":"Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450)","volume":"13","author":"De Ruysscher","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0014","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2021.07.035","article-title":"Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option","volume":"156","author":"Faehling","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2025.07.008_bib0015","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195149","article-title":"Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.prro.2025.07.008_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0018","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0019","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2018.11.017","article-title":"Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis","volume":"126","author":"Petrelli","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prro.2025.07.008_bib0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2018.06.400","article-title":"Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer","volume":"102","author":"Petty","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.07.008_bib0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2021.02.001","article-title":"A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis","volume":"154","author":"Spaggiari","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prro.2025.07.008_bib0022","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1186\/s12885-016-2952-3","article-title":"Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies","volume":"16","author":"Su","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prro.2025.07.008_bib0023","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ijrobp.2015.08.012","article-title":"Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage IV non-small cell lung cancer: Results of a multicenter phase 2 study from PPRA-RTOG, China","volume":"93","author":"Su","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.07.008_bib0024","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2021.08.011","article-title":"An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases","volume":"164","author":"Cao","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.prro.2025.07.008_bib0025","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/j.cllc.2019.06.024","article-title":"Long-term follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT","volume":"20","author":"H\u00f6rner-Rieber","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.prro.2025.07.008_bib0026","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.prro.2025.07.008_bib0027","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: A prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0028","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.07.008_bib0029","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","article-title":"Stereotactic ablative radiation for oligoprogressive cancers: Results of the randomized phase 2 STOP trial","volume":"121","author":"Schellenberg","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.07.008_bib0030","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0031","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.annonc.2022.12.004","article-title":"Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit","volume":"34","author":"Oosting","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0032","first-page":"311","article-title":"Oligometastatic non-small cell lung cancer: Current management","volume":"7","author":"Rom\u00e1n-Jobacho","year":"2021","journal-title":"J Clin Transl Res"},{"key":"10.1016\/j.prro.2025.07.008_bib0033","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0034","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.prro.2021.12.012","article-title":"Cost-effectiveness of treatment strategies for spinal metastases","volume":"12","author":"Kowalchuk","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e19364","article-title":"The value of immunotherapy: Comparison of annual cost per patient receiving immunotherapy versus chemotherapy in patients with non-small cell lung cancer","volume":"38","author":"Vasekar","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib0036","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ijrobp.2023.01.005","article-title":"Recent trends in Medicare payments for outpatient cancer care at the end of life","volume":"116","author":"Mantz","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.07.008_bib0037","article-title":"Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2025.07.008_bib38","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/j.cllc.2019.06.024","article-title":"Long-term Follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT","volume":"20","author":"H\u00f6rner-Rieber","year":"2019","journal-title":"Clin Lung Cancer"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025002152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025002152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T10:31:17Z","timestamp":1767695477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025002152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1879850025002152"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.07.008","relation":{},"ISSN":["1879-8500"],"issn-type":[{"type":"print","value":"1879-8500"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale Version 1.1 for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer With Radiosurgery","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}